Jeevan Scientific Technology Ltd

Jeevan Scientific Technology Limited has submitted its 28th Annual Report for the Financial Year 2025-26 in compliance with SEBI (LODR) Regulations, 2015. The report was dispatched to shareholders on September 3, 2026. The company's 28th Annual General Meeting (AGM) is scheduled for September 25, 2026, to be conducted via Video Conference (VC) or Other Audio-Visual Means. A letter providing the web-link to the Annual Report is also available on the company's website for members who haven't registered their email addresses. The report includes details on the Board of Directors, company vision, mission, quality policy, and financial statements for FY 2024-25.

Jeevan Scientific Technology Ltd has announced that its 28th Annual General Meeting (AGM) will be held on September 25, 2026, at 10:00 AM. The meeting will be conducted via Video Conference (VC) or Other Audio-Visual Means. The company has also dispatched its Annual Report for the Financial Year 2025-26 to shareholders on September 3, 2026, in compliance with SEBI (LODR) Regulations, 2015. A web-link to the Annual Report is available on the company's website for members who have not registered their email addresses.

Jeevan Scientific Technology Ltd has filed a statement confirming no deviation or variation in the utilization of funds raised through a preferential allotment. The report covers the quarter ended June 30, 2026. The company raised ₹3074 Lakhs on January 2, 2026. The statement details the utilization of these funds across various objectives including Capital Expenditure, Working Capital, and General Corporate Purposes, with no discrepancies noted against the original allocation.

Jeevan Scientific Technology Limited's Board of Directors convened on August 13, 2026, approving several key management changes and financial reporting items. The board considered and approved the Un-Audited Financial Results and Limited Review Report for the quarter ended June 30, 2026. Significant personnel decisions include the re-appointment of Mrs. Snigdha Mothukuri as Whole Time Director for three years from November 2, 2026, and the continuation and subsequent re-appointment of Mr. Nageswar Rao Yarllagadda as Whole Time Director beyond the age of 70, also for three years from June 23, 2027. Additionally, Mr. Suryaprakasa Rao Bommisetti was re-appointed as an Independent Director for five years from March 25, 2027, and Mr. Kolli Srinivas Rao was appointed as an additional Independent Director for five years from August 13, 2026. The notice for the Annual General Meeting for FY 2025-26, scheduled for September 25, 2026, was also approved.

Jeevan Scientific Technology Limited announced its unaudited financial results for the quarter ended June 30, 2026. The results were considered and approved at a Board Meeting held on August 13, 2026. The meeting also addressed several key management and corporate governance matters, including re-appointments of directors and the schedule for the upcoming Annual General Meeting (AGM) for FY 2025-26, which is set for September 25, 2026.

Jeevan Scientific Technology Limited's Board of Directors convened on August 13, 2026, approving the un-audited financial results for the quarter ended June 30, 2026 (Standalone and Consolidated). The board also approved several re-appointments of Whole Time Directors and Independent Directors, subject to shareholder approval. These include the re-appointment of Mrs. Snigdha Mothukuri and Mr. Nageswar Rao Yarllagadda as Whole Time Directors, and Mr. Suryaprakasa Rao Bommisetti as an Independent Director. Additionally, Mr. Kolli Srinivas Rao was appointed as an additional Independent Director. The company also announced the Annual General Meeting for FY 2025-26 will be held on September 25, 2026, and distributed the Directors' Report and other related documents.

Jeevan Scientific Technology Ltd has announced a Board of Directors meeting scheduled for August 13, 2026. The meeting will primarily focus on considering and approving the unaudited financial results for the quarter ended June 30, 2026, along with the limited review report. Additionally, the board will discuss and decide on the date, time, and venue for the 28th Annual General Meeting (AGM) for FY 2025-2026, approve the AGM notice, Directors' Report, and appoint a scrutinizer for the e-voting process.

Jeevan Scientific Technology Ltd announced that the Central Drugs Standard Control Organization (CDSCO) has approved an increase in bed capacity at its Bioavailability/Bioequivalence (BA/BE) Study Centre in Hyderabad. The capacity has been enhanced from 132 beds and 6 ICU beds to 156 beds and 8 ICU beds. This approval follows a successful regulatory inspection and the company's application for enhancement. The increased capacity is expected to strengthen the company's clinical research infrastructure, improve operational capabilities, and allow for a higher volume of BA/BE studies, supporting future business growth.

Jeevan Scientific Technology Ltd (JSTL) announced the successful completion of a USFDA inspection at its Bioanalytical Facility in Manikonda, Hyderabad. The inspection, conducted between July 20-24, 2026, reviewed BA/BE studies, operations, systems, and procedures. The USFDA inspectors closed the inspection with zero observations (No 483s), concluding that JSTL's team is well-trained, knowledgeable, and experienced with international regulatory requirements and good practices. The facility was deemed adequately designed, and the organization compliant with all applicable regulations.

Jeevan Scientific Technology Limited announced the successful completion of an inspection by the Central Drugs Standard Control Organization (CDSCO), Hyderabad Zonal Office. The inspection, conducted on June 24, 2026, was for the company's Bioavailability/Bioequivalence (BA/BE) Study Centre located in Balanagar, Hyderabad. This inspection was part of the company's application to add beds to its existing approved BA/BE Study Centre. Jeevan Scientific Technology fully cooperated with the inspection team, which assessed compliance with regulatory guidelines. The company is awaiting further regulatory evaluation following this inspection.